3-methyl-imidazo[1,2-c]pyrimidine | 33668-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3-methyl-imidazo[1,2-c]pyrimidine
• 英文别名: 3-Methylimidazo[1,2-c]pyrimidine
• CAS: 33668-76-7
• 化学式: C₇H₇N₃
• 分子量: 133.153
• InChiKey: LJGUCJKDGIDJBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• [EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS<br/>[FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
  申请人：PFIZER

  公开号：WO2010016005A1

  公开（公告）日：2010-02-11

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

  本发明涉及式(I)的化合物，及其药用可接受的盐，它们的合成以及它们作为CHK-1抑制剂的用途。
• NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME
  申请人：Kawamura Masahiro

  公开号：US20120132899A1

  公开（公告）日：2012-05-31

  A nitrogen-containing heterocyclic derivative represented by the following formula (1): wherein any “12-a” groups of R 1 to R 12 are independently a hydrogen atom, a fluorine atom, a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms or a substituted or unsubstituted heterocyclic group having 5 to 30 ring atoms; any “a” groups of R 1 to R 12 are independently a single bond which is bonded to L 1 ; L 1 is a single bond, a “b+1” valent substituted or unsubstituted hydrocarbon ring group having 6 to 30 ring carbon atoms or a “b+1” valent substituted or unsubstituted heterocyclic group having 5 to 30 ring atoms; HAr is a substituted or unsubstituted nitrogen-containing heterocyclic group; and “a” and “b” are independently an integer of 1 to 4, and at least one of “a” and “b” is 1. Also disclosed is a nitrogen-containing heterocyclic derivative represented by the following formula (21) or (31):

  一种含氮杂环衍生物，由以下公式（1）表示：其中R1至R12中的任何“12-a”基团独立地是氢原子、氟原子、具有6至30个环碳原子的取代或未取代芳基基团或具有5至30个环原子的取代或未取代杂环基团；R1至R12中的任何“a”基团独立地是与L1相结合的单键；L1是单键、具有6至30个环碳原子的“b+1”价取代或未取代的碳氢环基团或具有5至30个环原子的“b+1”价取代或未取代的杂环基团；HAr是取代或未取代的含氮杂环基团；“a”和“b”分别是1至4的整数，且至少有一个“a”和“b”为1。还公开了一种由以下公式（21）或（31）表示的含氮杂环衍生物：
• 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
  申请人：Braganza John Frederick

  公开号：US20110144084A1

  公开（公告）日：2011-06-16

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

  本发明涉及式（I）化合物及其药学上可接受的盐，它们的合成以及它们作为CHK-1抑制剂的用途。
• 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2328890B1

  公开（公告）日：2012-01-25